Abstract
Langerhans cell histiocytosis (LCH) is a rare systemic disorder characterized by the accumulation ofCD1a+/Langerin+LCHcells and wide‐ranging organ involvement. Langerhans cell histiocytosis was formerly referred to as histiocytosis X, until it was renamed in 1987. Langerhans cell histiocytosis β was named for its morphological similarity to skin Langerhans cells. Studies have shown thatLCHcells originate from myeloid dendritic cells rather than skin Langerhans cells. There has been significant debate regarding whetherLCHshould be defined as an immune disorder or a neoplasm. A breakthrough in understanding the pathogenesis ofLCHoccurred in 2010 when a gain‐of‐function mutation inBRAF(V600E) was identified in more than half ofLCHpatient samples. Studies have since reported that 100% ofLCHcases showERKphosphorylation, indicating thatLCHis likely to be a clonally expanding myeloid neoplasm. Langerhans cell histiocytosis is now defined as an inflammatory myeloid neoplasm in the revised 2016 Histiocyte Society classification. Randomized trials and novel approaches have led to improved outcomes for pediatric patients, but no well‐defined treatments for adult patients have been developed to date. AlthoughLCHis not fatal in all cases, delayed diagnosis or treatment can result in serious impairment of organ function and decreased quality of life. This study summarizes recent advances in the pathophysiology and treatment of adultLCH, to raise awareness of this “orphan disease”.